ICAM-1 SRC Binding Screening for Colorectal Cancer Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening and treating colorectal cancer are inadequate, particularly in accurately diagnosing and inhibiting metastasis, due to limitations in understanding the mechanisms of cancer cell metastasis and angiogenesis.
Innovation Solution
A method involving the measurement of ICAM-1 binding to SRC in cells treated with candidate materials to identify and select compounds that increase this binding, which can be used to develop therapeutic agents for inhibiting colorectal cancer metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If colonoscopy is used to screen and remove polyps, then colorectal cancer can be detected and treated early, but it causes side effects such as intestinal perforation, intestinal bleeding, and sleep apnea
Solution Approach 1:
The patent introduces ICAM-1 as an intermediary biomarker that mediates between the need for accurate cancer detection and the harmful effects of invasive procedures. By measuring ICAM-1 binding levels to SRC, the method provides a non-invasive screening approach that identifies high-risk patients who would benefit from colonoscopy, thereby reducing unnecessary procedural risks while maintaining detection accuracy.
Solution Approach 2:
The patent applies preliminary action by using ICAM-1 binding level measurement as a pre-screening tool before colonoscopy. This preliminary assessment identifies patients with high metastatic risk, allowing clinicians to prioritize colonoscopy for those most in need while avoiding unnecessary procedures in low-risk patients, thus reducing overall side effects while maintaining reliable detection.
2Reliability
If conventional screening methods are used, then colorectal cancer can be detected, but they are insufficient in accurately diagnosing and inhibiting metastasis
Solution Approach 1:
The patent changes the measurement parameter from general cancer detection to specific ICAM-1 binding level measurement to SRC. This parameter change provides quantitative data about metastatic potential, allowing for more precise diagnosis and risk stratification. The binding level serves as a continuous variable that correlates with metastatic risk, enabling more accurate prediction than conventional binary detection methods.
3Adaptability or versatility
If the mechanism of cancer cell metastasis and angiogenesis is not understood, then treatment development is limited, but investigating these mechanisms requires complex studies
Solution Approach 1:
The patent extracts the key mechanism element by focusing specifically on the ICAM-1 to SRC binding interaction. Rather than attempting to study all aspects of metastasis and angiogenesis simultaneously, the invention isolates this specific molecular interaction as the critical factor, simplifying the research approach while providing actionable insights for treatment development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach confirms ICAM-1 as a potential target for regulating cancer metastasis and angiogenesis, enabling the development of effective therapeutic agents that can improve treatment outcomes for colorectal cancer patients by inhibiting metastasis and angiogenesis.
Implementation Method 1
measuring the binding level of intracellular adhesion molecule 1 (ICAM-1) to SRC in the cell
Data Source
AI summary
The present disclosure relates to a method for screening a colorectal cancer inhibitor and, more specifically, to a method for screening a colorectal cancer inhibitor wherein a material increasing a binding level of ICAM-1 to SRC is selected as a therapeutic material. In the present disclosure, ICAM-1 is identified to regulate cancer metastasis and angiogenesis in an SRC-dependent manner, thereby exhibiting that ICAM-1 can be a potential target factor for developing a colorectal cancer therapeutic agent. Accordingly, a colorectal cancer therapeutic agent employing the target factor screened by the method of the present disclosure can increase the therapeutic effect for colorectal cancer patients.